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Background: There is a recognized need for an improved diagnostic test to assess
post-chemotherapeutic treatment outcome in visceral leishmaniasis (VL) and to diagnose
post kala-azar dermal leishmaniasis (PKDL). We previously demonstrated by ELISA and a
prototype novel rapid diagnostic test (RDT), that high anti-Leishmania IgG1 is associated
with post-treatment relapse versus cure in VL.
Methodology: Here, we further evaluate this novel, low-cost RDT, named VL Sero
K-SeT, and ELISA for monitoring IgG1 levels in VL patients after treatment. IgG1 levels
against L. donovani lysate were determined. We applied these assays to Indian sera from
cured VL at 6 months post treatment as well as to relapse and PKDL patients. Sudanese
sera from pre- and post-treatment and relapse were also tested.
Results: Of 104 paired Indian sera taken before and after treatment for VL, when
deemed clinically cured, 81 (77.9%) were positive by VL Sero K-SeT before treatment;
by 6 months, 68 of these 81 (84.0%) had a negative or reduced RDT test line intensity.
ELISAs differed in positivity rate between pre- and post-treatment (p = 0.0162). Twenty
eight of 33 (84.8%) Indian samples taken at diagnosis of relapse were RDT positive. A
comparison of Indian VL Sero K-SeT data from patients deemed cured and relapsed
confirmed that there was a significant difference (p < 0.0001) in positivity rate for
the two groups using this RDT. Ten of 17 (58.8%) Sudanese sera went from positive
to negative or decreased VL Sero K-SeT at the end of 11–30 days of treatment.
Forty nine of 63 (77.8%) PKDL samples from India were positive by VL Sero K-SeT.
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Conclusion: We have further shown the relevance of IgG1 in determining clinical status
in VL patients. A positive VL Sero K-SeT may also be helpful in supporting diagnosis of
PKDL. With further refinement, such as the use of specific antigens, the VL Sero K-SeT
and/or IgG1 ELISA may be adjuncts to current VL control programmes.
Keywords: visceral leishmaniasis, serology, treatment, relapse, cure, IgG1, RDT, PKDL
INTRODUCTION
Visceral leishmaniasis (VL; kala-azar), is caused by the protozoan
parasites Leishmania donovani in Asia, Africa and the Middle
East and Leishmania infantum in Europe and South America.
These parasites are transmitted by blood-feeding female
phlebotomine sand flies. Symptomatic VL is usually fatal if
untreated. Symptoms include prolonged fever>14 days, wasting,
splenomegaly, hepatomegaly and anemia (Sundar and Rai, 2002).
While VL is present in about 75 countries, the majority (90%) of
cases in 2015 occurred in India, Sudan, South Sudan, Ethiopia,
Somalia, Kenya, and Brazil (World Health Organization, 2017),
where it is closely linked to poverty, both as cause and effect
(Boelaert et al., 2009; Sarnoff et al., 2010).
Following clinical suspicion of VL, serology is used
for diagnosis. Techniques vary by region and include the
immunofluorescence antibody test (IFAT), direct agglutination
test (DAT), enzyme linked immunosorbent assay (ELISA), and
detection of IgG against recombinant antigens rK39 or rK28
(Singh and Sundar, 2015). In India the DAT and rK39 serology
are used, with a positive result in either test indicative of exposure
to infection with L. donovani. For confirmatory parasitological
diagnosis, seropositive individuals undergo spleen, bone marrow
or lymph node biopsy to search for the intracellular amastigote
stage in films of Giemsa-stained aspirates. These are invasive,
costly and potentially hazardous techniques with low and
variable sensitivities ranging from 53 to 99% (Singh and Sundar,
2015).
VL is treated with antimonials, miltefosine, paromomycin,
amphotericin B, liposomal amphotericin (AmBisome) or drug
combinations (World Health Organization, 2010). Currently,
post-treatment outcome is determined by assessment of clinical
signs and symptoms, initially on the last day of drug treatment
and, in India, again 6 months after administration of the last
dose (World Health Organization, 2010). Possible outcomes
are: cure; relapse; death (by VL or not); post kala-azar dermal
leishmaniasis (PKDL); loss to follow up. However, recent studies
from India and Nepal have reported relapse rates of between
1.4 and 20%, including up to and beyond 12 months following
the end of treatment (Burza et al., 2013, 2014; Rijal et al.,
2013). In Sudan, relapse rates around 6% have been reported
(Gorski et al., 2010; Atia et al., 2015). Patients who relapse
face a further biopsy procedure to confirm the presence of
parasites.
PKDL is a non-painful sequela of VL occurring in over 50%
of cases in Sudan (Zijlstra et al., 2003) but is far less prevalent
in South Asia (Zijlstra et al., 2003; Uranw et al., 2011). PKDL is
less reported in L. infantum endemic regions where cases have
mostly been associated with HIV/AIDS (Ridolfo et al., 2000;
Bittencourt et al., 2003; Celesia et al., 2014), other co-infections
(Trindade et al., 2015) or immune suppression (Roustan et al.,
1998). PKDL manifests between 0.5 months to one or more
years after apparently successful VL treatment (Musa et al., 2002;
Uranw et al., 2011; Singh et al., 2012; Moulik et al., 2017) and
may occasionally occur without a prior episode of VL (el Hassan
et al., 1992; Zijlstra et al., 2003; Das et al., 2012, 2016). PKDL is
suspected based on dermal manifestations that are non-specific
and diagnosis is made on previous VL treatment history and
confirmed parasitologically by microscopy of slit skin smear or
biopsy or PCR (Zijlstra et al., 2017). Conventional serology is
likely to remain positive from the earlier VL and there is no test
in use to predict PKDL (Gidwani et al., 2011). The high parasite
density in PKDL skin provides a source of infection to sand
flies and thus sustains long term transmission and endemicity
(Molina et al., 2017; Mondal et al., 2018).
An unresolved crucial question is how to identify
asymptomatic infected individuals simply and reliably (as
defined by seropositivity, lack of clinical symptoms and no
prior history of VL) who will progress to active VL. High DAT
and/or rK39 ELISA titres have been associated with increased
risk of progression in the Indian subcontinent but as yet there
is no single rapid test in use for this purpose (Hasker et al.,
2014; Chapman et al., 2015). To improve outcome monitoring
of VL and disease control, the World Health Organization has
identified the vital need for a marker of post-chemotherapeutic
cure, and the high priority incorporation of such a biomarker
into a point-of-care rapid diagnostic test (RDT) (World Health
Organization, 2012). Such a test should meet the “ASSURED”
criteria of being: affordable; sensitive (few false negatives);
specific (few false positives); user-friendly, requiring minimal
training; rapid; robust, not requiring cold-storage; equipment-
free, and deliverable to those who need it (Peeling et al.,
2006).
We have previously shown that high anti-Leishmania IgG1
ELISA titers are associated with treatment failure, whereas, in
cases deemed to be cured following chemotherapy, IgG1 levels
diminish significantly by 6 months post-treatment and only IgG1
gave this level of discrimination (Bhattacharyya et al., 2014a).
We demonstrated this by ELISA against L. donovani whole
cell lysate, and then adapted the assay to a prototype lateral
flow immunochromatographic RDT. Here, we present further
evaluation of this RDT, called VL Sero K-SeT, to indicate cure
after VL treatment in a larger, paired, sample set and to confirm
relapse. We also performed western blot on the same sample set.
Additionally we show the potential utility of VL Sero K-SeT and
other IgG1 assays to confirm PKDL.
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METHODS
Ethics Statement
In India, the collection of samples was approved by the
Ethics Committee of Banaras Hindu University, Varanasi.
In Sudan approval was by the Ethical Research Committee,
Faculty of Medicine, University of Khartoum and the National
Health Research Ethics Committee, Federal Ministry of Health,
Sudan. Written informed consent was obtained from adult
subjects included in the study or from the parents or
guardians of individuals <18 years of age. In Nepal, informed
consent was obtained from all the participants and the
ethical committee of the B.P. Koirala Institute of Health
Sciences (BPKIHS) approved the study. This research was
also approved, as part of the EC NIDIAG project, by the
London School of Hygiene and Tropical Medicine Ethics
Committee.
Sources of Sera/Plasma
We retrospectively selected sera or plasma from an archive of
different VL disease states. Samples had been collected in VL
endemic regions, namely Muzaffarpur in Bihar, India after 2007
and in 2013 in Gedaref, Sudan. Sample sizes used during this
evaluation were dependent on availability of appropriate samples
and reagents.
In India, cases of VL had been diagnosed by positive
rK39 serology and/or parasitologically by microscopy of splenic
aspirates. In Sudan active cases of VL had been diagnosed
by microscopy of bone marrow or lymph node aspirates in
conjunction with serological assays. These diagnoses were made
according to their respective national procedures, prior to the
present study. Sera/plasma were stored at −80◦C until use.
All patients were HIV negative. We have previously observed
that serum and plasma derived from the same sample show
no difference in IgG titer in ELISA against L. donovani lysate
(unpublished observations), although we have not specifically
assessed IgG1 with both sample types.
India
Indian sample types are described in Table 1. We have previously
found that in Indian VL, IgG1 titer up to day 30 post-treatment
initiation is not statistically significantly different from pre-
treatment (Bhattacharyya et al., 2014a) and therefore we consider
these as “pre-treatment” in paired samples for the purposes of this
study. Treatment of VL was with single-dose AmBisome alone or
with 10 days of miltefosine. PKDL was treated with miltefosine
for 84 days. DAT and rK39 ELISA were conducted prior to
the present study as part of standard diagnostic procedures in
India.
Sudan
Sudanese paired serum samples (n = 17 pairs) were taken
on day of diagnosis of VL and at the end of treatment at
11 days (AmBisome), 17 days (sodium stibogluconate (SSG)
+ paromomycin), or 30 days (SSG only). These samples were
previously tested for IgG1 by ELISA (Bhattacharyya et al., 2014a).
Additional Sudanese serum samples used in the present study
were unpaired treated individuals (n= 2) taken an unknown time
TABLE 1 | Indian sample types and total numbers tested by IgG1 assays.
Sample type Definition n
Pre- and
post-treatment pairs,
deemed cured
Treated for VL, with improvement in
clinical symptoms and no evidence of
relapse at any time 6 months after
treatment. Samples were taken at or
around the start of treatment and at 6
months.
105 pairs
Relapse VL treated and subsequently relapsed
to active disease. Sampled at the
time of relapse diagnosis.
33
PKDL Samples taken at or up to 30 days
after diagnosis of PKDL. Parasite
infection was confirmed by PCR or a
slit-skin smear or biopsy.
63
Asymptomatic Asymptomatic seropositive, on the
basis of DAT and/or rK39 ELISA,
without symptoms or history of VL.
Progressors (n = 4) developed VL
after sampling. Non-progressors
(n = 4) did not develop VL during
follow-up of at least 3 years.
8
Other diseases Malaria (n = 5); tuberculosis (n = 5),
rheumatoid arthritis (n = 1); dengue
(n = 1); multiple myeloma (n = 1).
13
Endemic healthy
control
Resident in VL endemic area,
seronegative by DAT and rK39 ELISA,
no history of VL, healthy.
30
after treatment, and relapse (n = 1). Sudanese Endemic Healthy
Control (EHC) samples had previously been tested by the IgG1
ELISA using the same antigen and were negative (Bhattacharyya
et al., 2014a) but were not retested here.
Antigen Production
Whole cell lysate of L. donovani strain MHOM/IN/80/DD8
isolated from India, and MHOM/SD/97/LEM3458 isolated from
Sudan, was prepared as described previously (Bhattacharyya
et al., 2014a). Lysate antigen was used for VL Sero K-SeT
development (strain LEM3458), ELISA and western blot (strain
DD8). Antigen preparation for western blot strips contained 50
µl of protease inhibitor cocktail (P8340, Sigma, UK) per 1ml of
L. donovani cells; centrifugation after sonication was 16,160 × g
for 45min at 4◦C.
ELISA for IgG1 Anti L. donovani
Duplicate ELISA plates were coated overnight at 4◦C with L.
donovani DD8 strain antigen prepared as above, at 2µg/ml in
coating buffer (35mM NaHCO3, 15mM NaCO3, pH 9.6), 100
µl/well. Plates were washed 3 times with phosphate buffered
saline (PBS) + 0.05% Tween 20 (PBST) prior to blocking with
200 µl/well PBS + 2% w/v non-fat milk powder (Premier
International Foods, UK) (PBSM) for 2 h at 37◦C, followed by
three PBST washes. Sera/plasma were diluted 1/100 in PBST+
2% w/v non-fat milk powder (PBSTM) and applied at 100
µl/well, incubated for 1 h at 37◦C then washed 6 times with
PBST. Mouse anti human IgG1-horse radish peroxidase (HRP)
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(ab99774, Abcam, UK) was diluted 1:5,000 in PBSTM and
incubated at 100µl/well, 37◦C for 1 h. Plates were washed 6 times
with PBST before the addition of 100 µl/well of freshly prepared
substrate solution (50mM citric acid, 50mM Na2HPO4, 2mM
o-phenylenediamine HCl, 0.009% H2O2). Plates with substrate
were incubated in the dark at room temperature for 10–15min
when the reaction was stopped with 100 µl/well of 1M H2SO4
and absorbance read at 490 nm. Each plate contained an EHC
sample as a negative serological control for determining the
positivity cut-off and a known seropositive VL sample as positive
control. All ELISA results reported are themean A490 of duplicate
plates.
RDT Production and Use
Whole cell lysate was prepared as described previously
(Bhattacharyya et al., 2014a) from L. donovani strain
MHOM/SD/97/LEM3458. The VL Sero K-SeT lateral flow
immunochromatographic tests were developed at Coris
BioConcept and consisted of a cassette with a nitrocellulose
membrane, a sample pad, a conjugate pad and an absorbent pad,
backed with a plastic strip. The nitrocellulose membranes were
sensitized with the L. donovani lysate antigen and anti-human
IgG1-specific antibody labeled with colloidal gold was dried on
the conjugate pad. This strip was housed in a plastic cassette with
two windows: the smaller buffer well and the long central test
window.
To perform the test, 3.5µl of serum/plasma was applied to the
test window at the point indicated by a dot (·) on the cassette,
followed immediately by 120 µl of supplied running buffer to the
buffer well (Figure 1). Devices were incubated flat, at ambient
temperature for 15min before being assessed visually. Any test
line at position T was considered a positive result if a control
line was also present at position C. Positive test line intensity was
assessed visually for samples from pre- and post-treatment VL
(Figure 1). A subset of samples was tested on different batches of
the VL Sero K-SeT. Readers of the RDTs were blinded to all the
corresponding ELISA results.
Western Blotting
Western blots were performed to visualize antigen recognition
in patients from the different clinical groups, as described in
Supplementary Material S1. Briefly, tricine SDS-PAGE gels were
made as per Schägger (2006). L. donovani DD8 lysate was
used as antigen with sera/plasma diluted 1 in 300 (Sudan)
or 1 in 400 (India) and detection was by mouse anti human
IgG1-HRP.
Statistical Analysis
We performed a two-tailed Fisher’s exact test on Indian VL
Sero K-SeT and IgG1 ELISA data to calculate p-values between
samples from pre- and matched 6 months post-treatment
(deemed cured), separately between post-treatment and relapse,
and between post-treatment and PKDL. Cut-off for the IgG1
ELISA was calculated as the mean absorbance of the EHC
samples plus 3 standard deviations.
RESULTS
IgG1 Diminishes by 6 Months in Cured VL
Patients
Samples taken from Indian patients before or at the outset of
therapy, were compared by VL Sero K-SeT and IgG1 ELISA with
paired samples taken 6 months later when the individuals were
deemed cured. Both IgG1 assay methods showed a statistically
significant difference in positivity rate between pre- and post-
treatment samples (p = 0.0162 and p < 0.0001 for ELISA
and RDT, respectively) (Figure 2). A consistent and strongly
significant difference was also observed between cured vs.
relapsed samples (p < 0.0001), again with both IgG1 assay
methods (Figure 2).
A subset of pre- and post-treatment of the cured pairs samples
(n = 87) was tested on different batches of the VL Sero K-SeT,
with agreement between individual RDTs of 92.0% (80/87).
Changes in IgG1 Levels by ELISA and VL
Sero K-SeT
ELISA absorbance and corresponding VL Sero K-SeT results for
individual samples are given in Supplementary Material S2. Of
the 80 Indian paired samples tested for anti L. donovani IgG1
by ELISA, 54 (67.5%) were positive before treatment. Of these,
51/54 declined in titer: 21/51 (representing 26.3% of the total 80)
went from positive to negative and 30/51 (representing 37.5% of
the total 80) had reduced IgG1 at 6 months when deemed cured
(Figure 2 and Table 2). Twenty one (26.3%) paired cured sera
were negative by IgG1 ELISA before treatment and remained so
at 6 months.
Overall, including those negative at the start, at 6 months
after treatment 79/104 (76.0%) were negative by VL Sero K-
SeT (Table 2). VL Sero K-SeT results were additionally assessed
according to whether the Indian 6 month post-treatment (cure)
sample had a decreased or not decreased test line intensity
compared to the paired pre-treatment sample. Of the 104 paired
samples tested by VL Sero K-SeT from deemed cured Indian
VL patients, 81 (77.9%) were positive at start of treatment
(Table 2); of these, 68/81 (84.0%) had either become negative
or had a visibly reduced test line intensity at 6 months
when deemed cured. Thirteen (12.5%) initially RDT positive
individuals showed no visible decrease in RDT band intensity at
6 months, despite being deemed cured, and none became positive
from negative.
Ninety four percent of samples positive by ELISA at pre-
treatment, decreased in seropositivity; for VL Sero K-SeT, this
proportion was 84%. However, at 6 months post-treatment, the
ELISA was more likely to remain positive than the RDT, using
the cut-off value established for the IgG1 ELISA.
Seventy nine Indian samples were tested by both VL Sero K-
SeT and ELISA. Of these samples, the RDT was more likely than
the ELISA to be positive with pre-treatment samples (78.5 vs.
67.1%) and negative with 6 month samples (78.5 vs. 53.2%). Of
samples which remained positive at 6 months by both methods
(n = 14), the change in intensity of RDT test line generally
mirrored the change in ELISA absorbance value for the same
sample. Three of the Indian samples increased markedly in IgG1
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FIGURE 1 | Representative examples of VL Sero K-SeT test line intensity. C, control line; T, test line; dot (•) indicates where sample is applied. Test strip manufacture
was identical despite being housed in different cassettes. Image is best viewed in digital, color format.
FIGURE 2 | IgG1 anti L. donovani assays with Indian VL samples detect differences according to treatment outcome. (A) ELISA A490 change between paired
pre-treatment samples and at 6 months post-treatment when deemed cured. Dashed line indicates cut-off (A490 = 0.128). Positivity rates with paired pre-treatment
and cured samples at 6 months (6 mth), and non-paired relapse (Rel) for (B) ELISA, (C) VL Sero K-SeT. *p < 0.0001, **p = 0.0162.
titer by ELISA at 6 months (Figure 2). Two of these accorded
with a corresponding rise in VL Sero K-SeT test line intensity;
for the third sample, both pre-treatment and 6 month RDTs were
negative (Figure 2A).
Sudanese paired samples taken before and immediately after
treatment (11–30 days later) were similarly assessed (Table 2).
For Sudanese paired samples prior to treatment, 13/17 (76.5%)
were positive by VL Sero K-SeT and at completion of treatment,
10/13 (76.9%) had a negative or reduced test line intensity
(Table 2). If taken as a single time point at the end of treatment,
10/17 (58.8%) Sudanese VL patients had negative VL Sero K-
SeT result. Four (23.5%) of the Sudanese treated individuals
were negative pre-treatment, similar to the proportion of Indian
samples (22.1%). Two additional un-paired treated Sudanese
samples were negative by RDT (not shown).
IgG1 Western Blot Confirmed
Negative/Declined RDT in Cure
For a subset of 25 of the paired Indian samples, western blots
mirrored the VL Sero K-SeT RDT findings, in that IgG1 declined
dramatically in all but one VL patient at 6 months follow up
after treatment (Supplementary Material S3). As with the RDT,
the blots showed that samples that were positive and detecting
many antigens before treatment had become negative or reduced
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TABLE 2 | Change in IgG1 response of pre- and post-treatment paired samples
from India and Sudan.
Change in IgG1 response ELISA A490 VL Sero K-SeT test line intensity
India n (%) India n (%) Sudan n (%)
Positive to negative 21 (26.3%) 56 (53.8%) 7 (41.2%)
Positive clear decrease 30 (37.5%) 12 (11.5%) 3 (17.6%)
Positive no clear decrease 3 (3.8%) 13 (12.5%) 3 (17.6%)
Negative no change 21 (26.3%) 23 (22.1%) 3 (17.6%)
Negative to positive 5 (6.3%) 0 (0%) 1 (5.9%)
Total 80 (100%) 104 (100%) 17 (100%)
in intensity by 6 months. Corresponding RDT images are shown
in Supplementary Material S4.
Elevated IgG1 in VL Relapse
For 33 Indian patients for whom we had unpaired samples
at the time of relapse, the VL Sero K-SeT was 84.8%
(28/33) positive and ELISA 91.3% (21/23) positive, confirming
relapse. Of the 23 samples tested by ELISA that were also
tested by RDT, 19 gave the same result by both assays
(Supplementary Material S2). The single available Sudanese
relapse sample was IgG1 positive (Supplementary Material S5).
Twenty five of the Indian samples and the single Sudanese sample
were also tested on western blot for IgG1 against L. donovani
lysate antigen and showed concordance between the RDT and
blots (Supplementary Materials S2, S5). For two of the 33 Indian
relapse samples, a paired pre-treatment sample was available.
Both individuals were VL Sero K-SeT positive at both time points.
All samples from other diseases, namely malaria, tuberculosis,
dengue fever, rheumatoid arthritis, and multiple myeloma were
negative by VL Sero K-SeT, as were all samples from endemic
healthy controls.
VL Sero K-SeT Can Provide Evidence for
PKDL but Not for Its Cure
Of the 63 PKDL samples tested, 49 (77.8%) were positive by
VL Sero K-SeT and of the subset of 45 tested by IgG1 ELISA,
43 (95.6%) were positive (Supplementary Material S2). A subset
of 10 VL Sero K-SeT-positive PKDL samples were tested by
western blot, of which 9 showed discernible bands. Images of the
blots and their corresponding VL Sero K-SeT RDTs are shown
in Supplementary Material S6. There was a highly statistically
significant difference between post-treatment cured samples at
6 months and PKDL by both VL Sero K-SeT and IgG1 ELISA
(Fisher’s exact p < 0.0001 for both assays).
Seventeen of the 63 individuals with PKDL provided between
1 and 5 additional sequential follow-up samples over intervals
ranging from 15 to 365 days post-treatment. These PKDL post-
treatment sequential samples retained the initial RDT result in
12/17 (70.6%) cases, decreased in 3/17 (17.6%), increased slightly
in one case (5.9%) and varied between positive and negative over
time in one case (5.9%).
IgG1 Can Indicate Progression From
Asymptomatic Status
When samples from asymptomatic seropositive individuals who
later progressed to symptomatic disease (progressors, n = 4)
were tested on the VL Sero K-SeT, all gave a positive test
result (Supplementary Material S7). In contrast, 4 individuals
who were seropositive but did not develop symptomatic VL
were negative by VL Sero K-SeT. Thus, in our limited
sample size, elevated IgG1 levels, as detected by VL Sero K-
SeT, were associated with progression to symptomatic disease.
This result was corroborated by ELISA and western blot
(Supplementary Material S7).
DISCUSSION
Conventional serology for VL diagnosis relies on detecting the
overall IgG response. This has been reported to remain elevated,
often for years, after treatment (Bhattarai et al., 2009; Gidwani
et al., 2011; Srivastava et al., 2013). This makes current serology
unsuitable for timely monitoring of treatment outcome. We
have previously found using ELISA that a decreased or negative
anti Leishmania IgG1 titer at 6 months post-treatment can be
indicative of VL cure, whereas elevated IgG1 levels are associated
with post-chemotherapeutic relapse (Bhattacharyya et al., 2014a).
Monitoring of Post-treatment Outcomes
Here we used a larger panel of paired samples to assess the
IgG1 response as detected by the rapid test, VL Sero K-SeT,
where 77.9% of Indian samples were positive before treatment
and of these 69.1% had become negative 6 months later when
deemed cured (Table 2). In total, 76% of 6 month samples
were negative, a significant difference from pre-treatment (p <
0.0001). Of those still positive at 6 months using this RDT, we
found that a diminished test line intensity was also consistent
with cure. This decline was corroborated by ELISAs, and despite
slight differences in the antigen preparations. We have found no
difference in performance of the VL Sero K-SeT when DD8 strain
antigen is used instead of LEM3458 (unpublished observations).
Thus, the VL Sero K-SeT is a promising innovation, although
there is a need to improve further its discriminative capacity.
Sudanese samples declined from positive to negative or
decreased VL Sero K-SeT test line intensity in 76.9% of patients
immediately after treatment, no more than 30 days after the
first sample. This apparently rapid drop in IgG1 was not seen
in Indian samples and could be due to the overall lower IgG
titer observed in Sudanese samples (Bhattacharyya et al., 2014b;
Abass et al., 2015). Thus, a small drop in IgG1 titer could have
taken these samples below the detection limit of the VL Sero
K-SeT. This may suggest that the VL Sero K-SeT can be used
before 6 months to indicate cure or relapse in eastern Africa. The
unexpectedly low sensitivity of the VL Sero K-SeT at the start of
treatment for both Indian (77.9%) and Sudanese (76.5%) samples
does not hinder the subsequent assessment of cure at 6 months,
because a negative IgG1 result at 6 months can indicate cure. In
addition, we do not propose to use IgG1 assays as a diagnostic for
active VL but rather to assist with confirming cure, relapse and
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PKDL, all of which currently lack an appropriate diagnostic test.
With Indian samples, where there was discrepancy between VL
Sero K-SeT and ELISA, the RDT was generally more accurate,
being positive with pre-treatment and negative with 6 month
samples (Supplementary Material S2). As for the Indian sera,
the strength of RDT test line intensity broadly corresponded with
ELISA signal for an individual sample.
Elevated levels of IgG1 were associated with VL relapse in
both assays here for Indian samples. Likewise, the single Sudanese
relapse patient was positive by VL Sero K-SeT, whilst 2 treated
individuals were negative. We do not know the length of time
between treatment and relapse for relapsed individuals (India
and Sudan), or the outcome of treated Sudanese individuals.
Burza et al. (2014) advised that patient follow-up should be
extended from 6 to 12 months as 50–85% of relapses have been
found to occur 6 to ≥12 months post-treatment (Rijal et al.,
2013; Burza et al., 2014). Our evaluations of a limited number
Nepalese relapse samples eluted from filter paper indicated that,
although encouraging, elution volumes and conditions need
further optimisation before they can be more extensively used
with VL Sero K-SeT (data not shown).
We found that in Indian cases who relapsed, the RDT
positivity rate was significantly different from 6 month samples
from patients deemed cured (p < 0.0001). Thus, the VL Sero
K-SeT, with Indian samples, can contribute to distinguishing
patients deemed cured from those who have relapsed. Of the
13 Indian patients deemed cured at 6 months but who had no
clear decrease in VL Sero K-SeT test line intensity (Table 2), none
is known to have relapsed with VL. However, the quantitative
ELISA did detect an IgG1 decrease in these samples, consistent
with cure. Apparent relapses might however, occasionally include
re-infections given the highly endemic locations (Morales et al.,
2002). Although beyond the scope of the present study, the
inclusion of parasite genotyping in a future study would be an
advantage.
Cases co-infected with HIV and VL were not included in the
present study. Serological diagnosis is less reliable in HIV/VL
co-infection (Cota et al., 2012; Abass et al., 2015) and the
dynamics of IgG1 response in HIV/VL co-infections need to be
determined. Other techniques such as a loopmediated isothermal
amplification (LAMP) or qPCR detecting parasite DNA might
have the potential to discriminate cure from relapse in HIV/VL
patients but are currently less accessible than immunological tests
(Mukhtar et al., 2018).
PKDL
Indian individuals with PKDL tested here were defined as being
with or without a previous history of VL, presenting with a
dermal macular, papular or nodular rash often starting on the
face with further spread to other parts of the body without loss
of sensation. VL Sero K-SeT and IgG1 ELISA results suggest
that these assays might contribute to PKDL case detection, as
found by a study by Saha et al. (2005), whereas conventional
serology may be of limited utility (Gidwani et al., 2011). Our data
did not assess the predictive value of IgG1 for development of
PKDL.
Where the information was available with our sample set,
we did not observe an association between elevated IgG1 and
macular vs. polymorphic PKDL presentation, this is in contrast
to the report of Mukhopadhyay et al. (2012). For a subset of these
PKDL samples, we also tested sequential samples taken up to
1 year after the initial sample. We did not observe a consistent
decrease in IgG1 after PKDL treatment.
Progression From Asymptomatic to Active
VL
Asymptomatic, seropositive cases outnumber active VL cases
(Bern et al., 2007; Ostyn et al., 2011; Hasker et al., 2013; Hirve
et al., 2016; Saha et al., 2017) but a proportion are at elevated risk
of progressing to active VL (Gidwani et al., 2009; Topno et al.,
2010; Ostyn et al., 2011). Asymptomatics have been reported to
occasionally have detectable parasites by PCR or culture of blood
(le Fichoux et al., 1999; Costa et al., 2002; Bhattarai et al., 2009;
Srivastava et al., 2013). Therefore, neither standard seropositivity
nor parasitaemia are indicators of progression to clinical disease.
Gidwani et al. (2009) found that this progression to VL occurred
up to 2 years after serological positivity.
Our limited sample size of seropositive asymptomatic
individuals were identified during a community serological
screening study, before the present study. Those who later
progressed to clinical VL were positive by VL Sero K-SeT and
ELISA, whilst those who did not progress were negative by both
assays. High titres in both DAT and rK39 ELISA have been
indicative of progression in larger studies (Ostyn et al., 2011;
Hasker et al., 2014). However, this combination of tests requires
laboratory facilities, therefore it would be desirable to have an
RDT that could predict progression.
Additional validation of the VL Sero K-SeT should compare
larger cohorts who do and do not progress to VL.
Potential Clinical Application of IgG1 Tests
On the basis of the IgG1 responses reported here by VL Sero
K-SeT and ELISA, we propose that IgG1 levels may contribute
to monitoring the therapeutic outcome of VL, irrespective of
whether there is a pre-treatment sample or result. With further
development and validation, IgG1 assays, including the VL Sero
K-SeT, which can be produced in large-scale at a cost of a
few Euros per test, can be used as an adjunct to the clinical
assessment of VL status following treatment. A negative, or
defined decrease in IgG1 result at 6 months post treatment
in India could be supportive of the clinical assessment of
cure. Conversely, an un-paired positive or non-decreased paired
positive result at 6 months could indicate the need for additional
follow-up. In Sudan, the test may be applicable for defining cure
before 6 months. A positive IgG1 result in suspected PKDL or
relapse could support the presence of leishmaniasis compared to
differential diagnoses. Although western blots were supportive of
the use of IgG1, we did not specifically assess banding patterns,
and do not propose their use in VL diagnosis. However, we are
investigating the discriminative diagnostic potential of antigens
separated on acrylamide gels.
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Recommendations for Further Validation of
IgG1 Assays
We propose that a prospective study, with extended follow-up
of a larger cohort of treated VL patients, should be used to
validate the use of IgG1 ELISA and the VL Sero K-SeT for
confirming cure in all endemic areas and defining the optimal
time for testing, which may differ between regions. This longer
follow-up would also indicate the potential of elevated IgG1 to
predict relapse and PKDL and in turn, link these with different
treatment regimens. A more extensive study of PKDL is required
to determine the potential role of IgG1 in identifying PKDL as
distinct from leprosy and fungal skin diseases (Saha et al., 2005;
Mondal and Khan, 2011). In addition, use of the IgG1 assays
on a much larger panel of seropositive asymptomatic individuals
would help to define its role in predicting progression to VL. In all
cases, comparison with existing diagnostics, including definitive
parasitological methods, would directly assess the advantage of
IgG1 assays.
Technical refinement of the VL Sero K-SeT should consider
the use of electronic RDT readers to give an objective
assessment of test band intensity. In addition, the identification
of specific antigens suitable to replace the use of parasite lysate
would obviate issues regarding batch-to-batch variation. These
developments could improve precision of IgG1 readings and
reproducibility. A comparison of whole blood and serum/plasma
is also required for point-of-care use, although a study in
Bangladesh on various VLRDTs did find high agreement between
the two sample types (Ghosh et al., 2015).
CONCLUSION
IgG1 assays, particularly in the VL Sero K-SeT RDT format, may
be a useful adjunct in the assessment of VL treatment outcome
and diagnosis of PKDL, which have been identified as research
priorities for VL (World Health Organization, 2012). With
additional refinement and validation, the VL Sero K-SeT and
IgG1 ELISA could contribute to life-saving follow-up of treated
patients and to control programmemonitoring, surveillance, and
targeting of strategies for long-term control of VL.
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